Abstract Neuroinflammation is increasingly recognized as a key feature in the development of Alzheimers disease (AD), with tumor necrosis factor-alpha (TNF-) playing a crucial role in initiating inflammatory responses
Phase 2 Trial (published in NEJM, June 2023): 48-week randomised controlled trial 338 adults with obesity or overweight, without type 2 diabetes Tested against placebo At the 12mg dose, participants lost an average of 24.2% of their body weight over 48 weeks
Insurance companies may cover weight loss medications, but they are not required to cover them, so this is not always the case
This could happen if the treatment and control groups are not comparable- for example if doctors prescribed GLP-1s vs another diabetes medication for systematic reasons such as the health profile of the patient
The site mimics the look of a legitimate French pharmacy, using green medical visuals and urgency tactics (100 premiers clients) to convince consumers it is an approved, France-made medical solution